{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:18:35Z","timestamp":1785428315760,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CL112\/26-1"],"award-info":[{"award-number":["CL112\/26-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021374","name":"HBIGS","doi-asserted-by":"crossref","award":["none"],"award-info":[{"award-number":["none"]}],"id":[{"id":"10.13039\/501100021374","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001661","name":"Ruprecht-Karls-Universit\u00e4t Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The cleavage and polyadenylation endonuclease CPSF73 is thought to be the target of the anti-trypanosomal benzoxaboroles AN7973, acoziborole and AN11736. We previously showed that AN7973 inhibits mRNA processing. We here investigated whether the drug candidates acoziborole (for human sleeping sickness) and AN11736 (for nagana in cattle) have the same effect. We also affinity purified tagged CPSF73 from parasites without, or after, AN7973 treatment, and analysed differentially co-purified proteins by mass spectrometry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>AN11736 and acoziborole both inhibited mRNA processing, as demonstrated by decreased levels of spliced mRNAs and accumulation of di- and tri-cistronic mRNAs from the alpha-beta tubulin locus. Treating the cells with AN7973 for 30\u00a0min. did not significantly affect the proteins that copurified with CPSF73.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13104-022-06258-y","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T05:02:51Z","timestamp":1671253371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinically relevant benzoxaboroles inhibit mRNA processing in Trypanosoma brucei"],"prefix":"10.1186","volume":"15","author":[{"given":"Albina","family":"Waithaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,17]]},"reference":[{"issue":"5","key":"6258_CR1","doi-asserted-by":"publisher","first-page":"e0008261","DOI":"10.1371\/journal.pntd.0008261","volume":"14","author":"JR Franco","year":"2020","unstructured":"Franco JR, Cecchi G, Priotto G, Paone M, Diarra A, Grout L, et al. Monitoring the elimination of human african trypanosomiasis at continental and country level: update to 2018. PLoS Negl Trop Dis. 2020;14(5):e0008261. https:\/\/doi.org\/10.1371\/journal.pntd.0008261.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"6258_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.prevetmed.2013.10.024","volume":"113","author":"AP Shaw","year":"2014","unstructured":"Shaw AP, Cecchi G, Wint GR, Mattioli RC, Robinson TP. Mapping the economic benefits to livestock keepers from intervening against bovine trypanosomosis in Eastern Africa. Prev Vet Med. 2014;113(2):197\u2013210. https:\/\/doi.org\/10.1016\/j.prevetmed.2013.10.024.","journal-title":"Prev Vet Med"},{"key":"6258_CR3","doi-asserted-by":"publisher","first-page":"616865","DOI":"10.3389\/fvets.2021.616865","volume":"8","author":"WO Okello","year":"2021","unstructured":"Okello WO, MacLeod ET, Muhanguzi D, Waiswa C, Welburn SC. Controlling Tsetse flies and ticks using Insecticide treatment of cattle in Tororo district Uganda: cost benefit analysis. Front Vet Sci. 2021;8:616865. https:\/\/doi.org\/10.3389\/fvets.2021.616865.","journal-title":"Front Vet Sci"},{"issue":"7","key":"6258_CR4","doi-asserted-by":"publisher","first-page":"e0254558","DOI":"10.1371\/journal.pone.0254558","volume":"16","author":"Z Abro","year":"2021","unstructured":"Abro Z, Kassie M, Muriithi B, Okal M, Masiga D, Wanda G, et al. The potential economic benefits of controlling trypanosomiasis using waterbuck repellent blend in sub-saharan Africa. PLoS ONE. 2021;16(7):e0254558. https:\/\/doi.org\/10.1371\/journal.pone.0254558.","journal-title":"PLoS ONE"},{"issue":"4","key":"6258_CR5","doi-asserted-by":"publisher","first-page":"e0010300","DOI":"10.1371\/journal.pntd.0010300","volume":"16","author":"JA Ofori","year":"2022","unstructured":"Ofori JA, Bakari SM, Bah S, Kolugu MK, Aning GK, Awandare GA, et al. A longitudinal two-year survey of the prevalence of trypanosomes in domestic cattle in Ghana by massively parallel sequencing of barcoded amplicons. PLoS Negl Trop Dis. 2022;16(4):e0010300. https:\/\/doi.org\/10.1371\/journal.pntd.0010300.","journal-title":"PLoS Negl Trop Dis"},{"key":"6258_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(19)30612-7","author":"AK Lindner","year":"2019","unstructured":"Lindner AK, Lejon V, Chappuis F, Seixas J, Kazumba L, Barrett MP, et al. New WHO guidelines for treatment of gambiense human african trypanosomiasis including fexinidazole: substantial changes for clinical practice. Lancet Infect Dis. 2019. https:\/\/doi.org\/10.1016\/s1473-3099(19)30612-7.","journal-title":"Lancet Infect Dis"},{"key":"6258_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed5010014","author":"H De Koning","year":"2020","unstructured":"De Koning H. The drugs of sleeping sickness: their mechanisms of action and resistance, and a brief history. Trop Med Infect Dis. 2020. https:\/\/doi.org\/10.3390\/tropicalmed5010014.","journal-title":"Trop Med Infect Dis."},{"issue":"14","key":"6258_CR8","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1017\/s0031182016001268","volume":"143","author":"F Giordani","year":"2016","unstructured":"Giordani F, Morrison LJ, Rowan TG, HP DEK, Barrett MP. The animal trypanosomiases and their chemotherapy: a review. Parasitology. 2016;143(14):1862\u201389. https:\/\/doi.org\/10.1017\/s0031182016001268.","journal-title":"Parasitology"},{"issue":"10","key":"6258_CR9","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.4155\/fmc.11.80","volume":"3","author":"RT Jacobs","year":"2011","unstructured":"Jacobs RT, Plattner JJ, Nare B, Wring SA, Chen D, Freund Y, et al. Benzoxaboroles: a new class of potential drugs for human african trypanosomiasis. Future Med Chem. 2011;3(10):1259\u201378. https:\/\/doi.org\/10.4155\/fmc.11.80.","journal-title":"Future Med Chem"},{"issue":"6","key":"6258_CR10","doi-asserted-by":"publisher","first-page":"e1151","DOI":"10.1371\/journal.pntd.0001151","volume":"5","author":"RT Jacobs","year":"2011","unstructured":"Jacobs RT, Nare B, Wring SA, Orr MD, Chen D, Sligar JM, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human african trypanosomiasis. PLoS Negl Trop Dis. 2011;5(6):e1151. https:\/\/doi.org\/10.1371\/journal.pntd.0001151.","journal-title":"PLoS Negl Trop Dis"},{"key":"6258_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.11.028","author":"T Akama","year":"2017","unstructured":"Akama T, Zhang YK, Freund YR, Berry P, Lee J, Easom EE, et al. Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of animal african trypanosomiasis (AAT). Bioorg Med Chem Lett. 2017. https:\/\/doi.org\/10.1016\/j.bmcl.2017.11.028.","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"6258_CR12","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1586\/14787210.2014.959496","volume":"12","author":"G Eperon","year":"2014","unstructured":"Eperon G, Balasegaram M, Potet J, Mowbray C, Valverde O, Chappuis F. Treatment options for second-stage gambiense human african trypanosomiasis. Expert Rev Anti Infect Ther. 2014;12(11):1407\u201317. https:\/\/doi.org\/10.1586\/14787210.2014.959496.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"11","key":"6258_CR13","doi-asserted-by":"publisher","first-page":"e1008932","DOI":"10.1371\/journal.ppat.1008932","volume":"16","author":"F Giordani","year":"2020","unstructured":"Giordani F, Paape D, Vincent IM, Pountain AW, Fern\u00e1ndez-Cort\u00e9s F, Rico E, et al. Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. PLoS Pathog. 2020;16(11):e1008932. https:\/\/doi.org\/10.1371\/journal.ppat.1008932.","journal-title":"PLoS Pathog"},{"issue":"4","key":"6258_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2217\/fmb.11.20","volume":"6","author":"S Michaeli","year":"2011","unstructured":"Michaeli S. Trans-splicing in trypanosomes: machinery and its impact on the parasite transcriptome. Future Microbiol. 2011;6(4):459\u201374. https:\/\/doi.org\/10.2217\/fmb.11.20.","journal-title":"Future Microbiol"},{"issue":"2","key":"6258_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/15476286.2015.1130208","volume":"13","author":"H Koch","year":"2016","unstructured":"Koch H, Raabe M, Urlaub H, Bindereif A, Preusser C. The polyadenylation complex of Trypanosoma brucei: characterization of the functional poly(A) polymerase. RNA Biol. 2016;13(2):221\u201331. https:\/\/doi.org\/10.1080\/15476286.2015.1130208.","journal-title":"RNA Biol"},{"issue":"7121","key":"6258_CR16","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/nature05363","volume":"444","author":"CR Mandel","year":"2006","unstructured":"Mandel CR, Kaneko S, Zhang H, Gebauer D, Vethantham V, Manley JL, et al. Polyadenylation factor CPSF-73 is the pre-mRNA 3\u2019-end-processing endonuclease. Nature. 2006;444(7121):953\u20136. https:\/\/doi.org\/10.1038\/nature05363.","journal-title":"Nature"},{"key":"6258_CR17","doi-asserted-by":"publisher","first-page":"e1007315","DOI":"10.1371\/journal.ppat.1007315","volume":"14","author":"D Begolo","year":"2018","unstructured":"Begolo D, Vincent I, Giordani F, P\u00f6hner I, Witty M, Rowan T, et al. The trypanocidal benzoxaborole AN7973 inhibits trypanosome mRNA processing. PLoS Pathog. 2018;14:e1007315. https:\/\/doi.org\/10.1371\/journal.ppat.1007315.","journal-title":"PLoS Pathog"},{"issue":"38","key":"6258_CR18","doi-asserted-by":"publisher","first-page":"9616","DOI":"10.1073\/pnas.1807915115","volume":"115","author":"RJ Wall","year":"2018","unstructured":"Wall RJ, Rico E, Lukac I, Zuccotto F, Elg S, Gilbert IH, et al. Clinical and veterinary trypanocidal benzoxaboroles target CPSF3. Proc Natl Acad Sci USA. 2018;115(38):9616\u201321. https:\/\/doi.org\/10.1073\/pnas.1807915115.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6258_CR19","doi-asserted-by":"publisher","first-page":"e0258903","DOI":"10.1371\/journal.pone.0258903","volume":"16","author":"F Falk","year":"2021","unstructured":"Falk F, Kamanyi Marucha K, Clayton C. The EIF4E1-4EIP cap-binding complex of Trypanosoma brucei interacts with the terminal uridylyl transferase TUT3. PLoS ONE. 2021;16:e0258903. https:\/\/doi.org\/10.1371\/journal.pone.0258903.","journal-title":"PLoS ONE"},{"key":"6258_CR20","doi-asserted-by":"publisher","first-page":"e1006560","DOI":"10.1371\/journal.ppat.1006560","volume":"13","author":"E Mugo","year":"2017","unstructured":"Mugo E, Clayton C. Expression of the RNA-binding protein RBP10 promotes the bloodstream-form differentiation state in Trypanosoma brucei. PLoS Pathog. 2017;13:e1006560. https:\/\/doi.org\/10.1371\/journal.ppat.1006560.","journal-title":"PLoS Pathog"},{"issue":"9","key":"6258_CR21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016;13(9):731\u201340. https:\/\/doi.org\/10.1038\/nmeth.3901.","journal-title":"Nat Methods"},{"key":"6258_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.12688\/wellcomeopenres.15421.1","volume":"4","author":"M Tinti","year":"2019","unstructured":"Tinti M, G\u00fcther M, Crozier T, Lamond A, Ferguson M. Proteome turnover in the bloodstream and procyclic forms of Trypanosoma brucei measured by quantitative proteomics. Wellcome Open Research. 2019;4:152.","journal-title":"Wellcome Open Research"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-022-06258-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-022-06258-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-022-06258-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T09:14:17Z","timestamp":1671527657000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-022-06258-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,17]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6258"],"URL":"https:\/\/doi.org\/10.1186\/s13104-022-06258-y","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,17]]},"assertion":[{"value":"15 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"371"}}